By Denny Jacob
Clinical-stage company Pharvaris said the U.S. Food and Drug Administration lifted the clinical hold on the investigational new drug application for deucrictibant for the prophylactic treatment of hereditary angioedema attacks following a review of data from a study.
“The lift of the clinical hold in the U.S. enables us to progress the global development of deucrictibant for long-term prophylaxis,” including a resumed Phase 2 study in the U.S., said Chief Executive Berndt Modig.
The FDA placed clinical studies of deucrictibant on hold in August 2022.
Write to Denny Jacob at [email protected]
Read the full article here
